IL6 and neoplasm: Interleukin-6 (IL-6) is a pro-inflammatory cytokine involved in the immune response, and high serum IL-6 levels have been linked to poor outcomes in melanoma patients treated with ICIs, likely due to its role in promoting an immunosuppressive tumor microenvironment.